Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
31.87 (1y: +49%)
Market Cap 12.02 B P/E(ttm) 21.20
Enterprise Value 18.77 B P/B 3.70
MYL- NAS (USA)
Mylan Inc
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$31.87
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry		 vs
history
Cash to Debt 0.054
MYL's Cash to Debt is ranked lower than
60% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. MYL: 0.054 )
MYL' s 10-Year Cash to Debt Range
Min: 0.05   Max: 38.64
Current: 0.05
0.05
38.64
Equity to Asset 0.28
MYL's Equity to Asset is ranked lower than
56% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MYL: 0.28 )
MYL' s 10-Year Equity to Asset Range
Min: 0.26   Max: 0.9
Current: 0.28
0.26
0.9
Interest Coverage 3.6
MYL's Interest Coverage is ranked higher than
61% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.70 vs. MYL: 3.6 )
MYL' s 10-Year Interest Coverage Range
Min: 1   Max: 9
Current: 3.6
1
9
F-Score: 6
Z-Score: 1.92
M-Score: -2.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 16.30
MYL's Operating margin (%) is ranked higher than
83% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.80 vs. MYL: 16.30 )
MYL' s 10-Year Operating margin (%) Range
Min: -45.4   Max: 36
Current: 16.3
-45.4
36
Net-margin (%) 9.4
MYL's Net-margin (%) is ranked higher than
78% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. MYL: 9.4 )
MYL' s 10-Year Net-margin (%) Range
Min: -52.2   Max: 24.3
Current: 9.4
-52.2
24.3
ROE (%) 19.2
MYL's ROE (%) is ranked higher than
94% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. MYL: 19.2 )
MYL' s 10-Year ROE (%) Range
Min: -33.4   Max: 23.4
Current: 19.2
-33.4
23.4
ROA (%) 5.4
MYL's ROA (%) is ranked higher than
75% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. MYL: 5.4 )
MYL' s 10-Year ROA (%) Range
Min: -10   Max: 17.8
Current: 5.4
-10
17.8
ROC (Joel Greenblatt) (%) 35.20
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.40 vs. MYL: 35.20 )
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -46.2   Max: 90.9
Current: 35.2
-46.2
90.9
Revenue Growth (%) -0.6
MYL's Revenue Growth (%) is ranked lower than
56% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: -0.6 )
MYL' s 10-Year Revenue Growth (%) Range
Min: -4.6   Max: 33.2
Current: -0.6
-4.6
33.2
EBITDA Growth (%) 7
MYL's EBITDA Growth (%) is ranked higher than
86% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 7 )
MYL' s 10-Year EBITDA Growth (%) Range
Min: -4.7   Max: 72.5
Current: 7
-4.7
72.5
EPS Growth (%) 50
MYL's EPS Growth (%) is ranked higher than
97% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 50 )
MYL' s 10-Year EPS Growth (%) Range
Min: -25.8   Max: 75
Current: 50
-25.8
75
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

MYL Guru Trades in Q2 2012

Ray Dalio 509,310 sh (+71.72%)
Paul Tudor Jones 16,600 sh (+49.55%)
Scott Black 324,255 sh (+33.11%)
Tom Russo 3,500 sh (unchged)
Mario Gabelli 20,085 sh (unchged)
John Paulson 24,503,400 sh (unchged)
George Soros Sold Out
Pioneer Investments Sold Out
Steven Cohen 620,888 sh (-10.11%)
» More
Q3 2012

MYL Guru Trades in Q3 2012

Steven Cohen 2,096,003 sh (+237.58%)
Scott Black 354,828 sh (+9.43%)
Tom Russo 3,500 sh (unchged)
Mario Gabelli 20,085 sh (unchged)
John Paulson 24,503,400 sh (unchged)
Paul Tudor Jones Sold Out
Ray Dalio 50,489 sh (-90.09%)
» More
Q4 2012

MYL Guru Trades in Q4 2012

Ken Heebner 300,000 sh (New)
Louis Moore Bacon 100,000 sh (New)
Jim Simons 514,300 sh (New)
Joel Greenblatt 70,384 sh (New)
Steven Cohen 2,744,653 sh (+30.95%)
Scott Black 381,044 sh (+7.39%)
Mario Gabelli 20,085 sh (unchged)
John Paulson 24,503,400 sh (unchged)
Tom Russo 3,500 sh (unchged)
Ray Dalio 41,289 sh (-18.22%)
» More
Q1 2013

MYL Guru Trades in Q1 2013

Vanguard Health Care Fund 4,176,100 sh (New)
Paul Tudor Jones 32,400 sh (New)
Ray Dalio 292,989 sh (+609.61%)
Jim Simons 2,487,100 sh (+383.59%)
Mario Gabelli 20,085 sh (unchged)
Tom Russo 3,500 sh (unchged)
Ken Heebner Sold Out
Louis Moore Bacon Sold Out
Scott Black 370,954 sh (-2.65%)
John Paulson 18,073,400 sh (-26.24%)
Joel Greenblatt 16,825 sh (-76.1%)
Steven Cohen 311,554 sh (-88.65%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2013-03-31 Reduce -26.24%1.08%$27.45 - $31.01 $ 31.8710%18073400
Vanguard Health Care Fund 2013-03-31 New Buy0.48%$27.45 - $31.01 $ 31.8710%4176100
Joel Greenblatt 2013-03-31 Reduce -76.1%0.08%$27.45 - $31.01 $ 31.8710%16825
Ray Dalio 2013-03-31 Add 609.61%0.07%$27.45 - $31.01 $ 31.8710%292989
Joel Greenblatt 2012-12-31 New Buy0.11%$23.44 - $28.3 $ 31.8722%70384
Ray Dalio 2012-09-30 Reduce -90.09%0.14%$21.56 - $24.55 $ 31.8738%50489
Scott Black 2012-09-30 Add 9.43%0.11%$21.56 - $24.55 $ 31.8738%354828
Scott Black 2012-06-30 Add 33.11%0.27%$20.6 - $23.5 $ 31.8748%324255
George Soros 2012-06-30 Sold Out 0.14%$20.6 - $23.5 $ 31.8748%0
Ray Dalio 2012-06-30 Add 71.72%0.07%$20.6 - $23.5 $ 31.8748%509310
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Top Ranked Articles about Mylan Inc

Weekly Top Insider Sells: FIS, MYL, LMCA
December 24, 2012
According to GuruFocus Insider Data, these are the largest insider sells during the past week. The overall trend of insiders is illustrated in the chart below: Read more...
52-Week High Companies: MYL, CBE, CCI, CM
November 26, 2012
According to GuruFocus list of 52-week highs, these Guru stocks have reached their 52-Week Highs: Mylan Inc. (MYL), Cooper Industries Plc (CBE), Crown Castle International Corp. (CCI) and Canadian Imperial Bank of Commerce (CM). Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 21.20
MYL's P/E(ttm) is ranked higher than
72% of the 497 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.30 vs. MYL: 21.20 )
MYL' s 10-Year P/E(ttm) Range
Min: 9.95   Max: 112.56
Current: 21.2
9.95
112.56
P/B 3.70
MYL's P/B is ranked higher than
51% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. MYL: 3.70 )
MYL' s 10-Year P/B Range
Min: 0.96   Max: 6.83
Current: 3.7
0.96
6.83
P/S 1.90
MYL's P/S is ranked higher than
74% of the 654 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. MYL: 1.90 )
MYL' s 10-Year P/S Range
Min: 0.56   Max: 5.69
Current: 1.9
0.56
5.69
PFCF 16.00
MYL's PFCF is ranked higher than
82% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.96 vs. MYL: 16.00 )
MYL' s 10-Year PFCF Range
Min: 8.81   Max: 1402
Current: 16
8.81
1402
EV-to-EBIT 17.5
MYL's EV-to-EBIT is ranked higher than
71% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.43 vs. MYL: 17.5 )
MYL' s 10-Year EV-to-EBIT Range
Min: 6.6   Max: 181.7
Current: 17.5
6.6
181.7
PEG 1.7
MYL's PEG is ranked higher than
73% of the 263 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.22 vs. MYL: 1.7 )
MYL' s 10-Year PEG Range
Min: 0.37   Max: 29.44
Current: 1.7
0.37
29.44
Shiller P/E 55.1
MYL's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: vs. MYL: 55.1 )
MYL' s 10-Year Shiller P/E Range
Min: 7.45   Max: 55.1
Current: 55.1
7.45
55.1

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 6.6
MYL's Price/Net Current Asset Value is ranked higher than
84% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.20 vs. MYL: 6.6 )
MYL' s 10-Year Price/Net Current Asset Value Range
Min: 2.2   Max: 20.8
Current: 6.6
2.2
20.8
Price/DCF (Projected) 1.9
MYL's Price/DCF (Projected) is ranked higher than
77% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MYL: 1.9 )
MYL' s 10-Year Price/DCF (Projected) Range
Min: 0.6   Max: 1.7
Current: 1.9
0.6
1.7
Price/Median PS Value 0.6
MYL's Price/Median PS Value is ranked higher than
94% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. MYL: 0.6 )
MYL' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 1.5
Current: 0.6
0.2
1.5
Earnings Yield (Greenblatt) 5.70
MYL's Earnings Yield (Greenblatt) is ranked higher than
79% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. MYL: 5.70 )
MYL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 15
Current: 5.7
0.6
15
Forward Rate of Return (Yacktman) 2.75
MYL's Forward Rate of Return (Yacktman) is ranked higher than
83% of the 709 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 2.75 )
MYL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.1   Max: 38.9
Current: 2.75
3.1
38.9

Business Description

Mylan, Inc. was incorporated in Pennsylvania in 1970. The Company and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic and branded generic pharmaceuticals, specialty pharmaceuticals and active pharmaceutical ingredients ('API'). The Compapny has two reportable segments, the Generics Segment and the Specialty Segment. The principal markets for the Generics Segment products are proprietary and ethical pharmaceutical wholesalers and distributors, drug store chains, drug manufacturers, institutions, and public and governmental agencies primarily within the United States ('U.S.') and Canada, Europe, the Middle East and Africa, and Australia, Japan, India and New Zealand. The Generics Segment also focuses on developing API with non-infringing processes to partner with generic manufacturers in regulated markets such as the U.S. and the European Union ('EU') at market formation. The principal market for the Specialty Segment is pharmaceutical wholesalers and distributors primarily in the U.S. Its specialty pharmaceutical business is conducted through Dey, which competes primarily in the respiratory, severe allergy and psychiatry markets. Dey's products are primarily branded specialty nebulized, injectable and transdermal products for life-threatening conditions. Currently, Mylan markets more than 900 different products covering a vast array of therapeutic categories, to consumers in more than 140 countries and territories across the globe. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids, as well as some which are difficult to formulate and manufacture and typically have longer product life cycles than traditional generic pharmaceuticals, including high potency formulations, steriles, injectables, transdermal patches, controlled release and respiratory delivery products. Mylan utilizes a global approach to managing relationships with its suppliers. Matrix provides Mylan with significant vertical integration opportunities that have been significantly enhanced with the purchase of the former Merck Generics business. Its primary competitors include other generic companies (both major multinational generic drug companies and various local generic drug companies) and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:MYL.Germany
» More Articles for MYL

Headlines

Articles On GuruFocus.com
comment on MYL Jan 04 2013 
comment on MYL Jan 01 2013 
Weekly Top Insider Sells: FIS, MYL, LMCA Dec 24 2012 
A Merrier Christmas to These Insiders, Made the Most Money in Past Week’s Trades Dec 21 2012 
52-Week High Companies: MYL, CBE, CCI, CM Nov 26 2012 
Weekly Top Insider Sells: MSFT, GOOG, FB, MYL, and NEE Nov 05 2012 
52-Week High Companies: HD, MMC, MMM, MYL, PFE Sep 03 2012 
Four Ways to Make More and Lose Less Aug 09 2012 
Good value <$18 May 11 2012 
Teva Is Driving Forward Feb 28 2012 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK